Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 9/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4816869 | 0.84 | PTGS2 (0.42) | NR3C1MEN1ALDH1A1KMT2ANR3C2 | |
| SCHEMBL476769 | 0.78 | ALDH1A1 (0.47) | MEN1ALDH1A1KMT2A | |
| SCHEMBL4820423 | 0.77 | NR3C1 (0.38) | NR3C1NR3C2PGR | |
| SCHEMBL6585591 | 0.76 | NR3C1 (0.42) | NR3C1MEN1ALDH1A1KMT2ANR3C2 | |
| SCHEMBL6585677 | 0.75 | HSD11B1 (0.44) | NR3C1MEN1ALDH1A1KMT2ANR3C2 | |
| SCHEMBL6167953 | 0.75 | NR3C1 (0.35) | NR3C1NR3C2PGR | |
| SCHEMBL6585998 | 0.74 | NR3C1 (0.66) | NR3C1NR3C2PGR | |
| SCHEMBL14353045 | 0.70 | ALDH1A1 (0.44) | MEN1ALDH1A1KMT2A | |
| SCHEMBL14460714 | 0.69 | ALDH1A1 (0.46) | MEN1ALDH1A1KMT2A | |
| SCHEMBL30156542 | 0.69 | ALDH1A1 (0.46) | MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329753-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2008-02-12 | — | — | US | disclosed |
| EP-1492771-B1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20060229333-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-12 | — | — | US | disclosed |
| US-7109212-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2006-09-19 | — | — | US | disclosed |
| US-20050165050-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2005-07-28 | — | — | US | disclosed |
| US-6897224-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2005-05-24 | — | — | US | disclosed |
| EP-1492771-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040116694-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2004-06-17 | — | — | US | disclosed |
| WO-2003082827-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229333-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | NFKBIA, IL1B, IRF3 | NR3C1 2380/4885MEN1 4490/4885ALDH1A1 1538/4885 |
| US-20050165050-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | NFKBIA, IL1B, IRF3 | NR3C1 2380/4885MEN1 4490/4885ALDH1A1 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.